Biofrontera (BFRI) Projected to Post Quarterly Earnings on Thursday

Posted by Stephan Jacobs on Mar 17th, 2026

Biofrontera (NASDAQ:BFRI – Get Free Report) is expected to issue its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect the company to announce earnings of $0.29 per share and revenue of $16.1460 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 19, 2026 at 10:00 AM ET.

Biofrontera Trading Up 2.3%

NASDAQ BFRI opened at $0.89 on Tuesday. Biofrontera has a 12 month low of $0.54 and a 12 month high of $1.19. The stock has a market cap of $10.36 million, a PE ratio of -0.55 and a beta of 0.61. The stock’s 50 day moving average is $0.87 and its 200 day moving average is $0.88.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Rosalind Advisors Inc. increased its stake in shares of Biofrontera Inc. (NASDAQ:BFRI – Free Report) by 51.5% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 976,448 shares of the company’s stock after acquiring an additional 332,055 shares during the quarter. Biofrontera comprises about 0.3% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th largest holding. Rosalind Advisors Inc. owned approximately 9.63% of Biofrontera worth $695,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 10.08% of the company’s stock.

Biofrontera Company Profile

(Get Free Report)

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.